These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 23109735)

  • 21. Urgent need of cholera vaccines in public health-control programs.
    Clemens J; Holmgren J
    Future Microbiol; 2009 May; 4(4):381-5. PubMed ID: 19416006
    [No Abstract]   [Full Text] [Related]  

  • 22. A national cholera vaccine stockpile--a new humanitarian and diplomatic resource.
    Waldor MK; Hotez PJ; Clemens JD
    N Engl J Med; 2010 Dec; 363(24):2279-82. PubMed ID: 21105832
    [No Abstract]   [Full Text] [Related]  

  • 23. The value of cholera vaccines reassessed.
    Glass RI; Steele AD
    Lancet; 2005 Jul 2-8; 366(9479):7-9. PubMed ID: 15993211
    [No Abstract]   [Full Text] [Related]  

  • 24. Cholera vaccine plan splits experts.
    Cyranoski D
    Nature; 2011 Jan; 469(7330):273-4. PubMed ID: 21248807
    [No Abstract]   [Full Text] [Related]  

  • 25. Response to "questionable merits of the field trial of an oral killed whole cell cholera vaccine in Vietnam during 1998-2003" Vaccine 2007;25(8):1353-4.
    Thiem VD; Canh DG; Anh DD; Deen JL; von Seidlein L; Clemens JD; Holmgren J
    Vaccine; 2007 Nov; 25(47):7981-3. PubMed ID: 17933443
    [No Abstract]   [Full Text] [Related]  

  • 26. Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial.
    Sur D; Lopez AL; Kanungo S; Paisley A; Manna B; Ali M; Niyogi SK; Park JK; Sarkar B; Puri MK; Kim DR; Deen JL; Holmgren J; Carbis R; Rao R; Nguyen TV; Donner A; Ganguly NK; Nair GB; Bhattacharya SK; Clemens JD
    Lancet; 2009 Nov; 374(9702):1694-702. PubMed ID: 19819004
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Considerations for oral cholera vaccine use during outbreak after earthquake in Haiti, 2010-2011.
    Date KA; Vicari A; Hyde TB; Mintz E; Danovaro-Holliday MC; Henry A; Tappero JW; Roels TH; Abrams J; Burkholder BT; Ruiz-Matus C; Andrus J; Dietz V
    Emerg Infect Dis; 2011 Nov; 17(11):2105-12. PubMed ID: 22099114
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Introducing cholera vaccination in Asia, Africa and Haiti: a meeting report.
    Hall RH; Sack DA
    Vaccine; 2015 Jan; 33(4):487-92. PubMed ID: 25437100
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Euvichol story - Development and licensure of a safe, effective and affordable oral cholera vaccine through global public private partnerships.
    Odevall L; Hong D; Digilio L; Sahastrabuddhe S; Mogasale V; Baik Y; Choi S; Kim JH; Lynch J
    Vaccine; 2018 Oct; 36(45):6606-6614. PubMed ID: 30314912
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lessons learnt from 12 oral cholera vaccine campaigns in resource-poor settings.
    Hsiao A; Desai SN; Mogasale V; Excler JL; Digilio L
    Bull World Health Organ; 2017 Apr; 95(4):303-312. PubMed ID: 28479625
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral cholera vaccines and their impact on the global burden of disease.
    Wierzba TF
    Hum Vaccin Immunother; 2019; 15(6):1294-1301. PubMed ID: 30183486
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Maximizing protection from use of oral cholera vaccines in developing country settings: an immunological review of oral cholera vaccines.
    Desai SN; Cravioto A; Sur D; Kanungo S
    Hum Vaccin Immunother; 2014; 10(6):1457-65. PubMed ID: 24861554
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term effectiveness against cholera of oral killed whole-cell vaccine produced in Vietnam.
    Thiem VD; Deen JL; von Seidlein L; Canh DG; Anh DD; Park JK; Ali M; Danovaro-Holliday MC; Son ND; Hoa NT; Holmgren J; Clemens JD
    Vaccine; 2006 May; 24(20):4297-303. PubMed ID: 16580760
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimal allocation of the limited oral cholera vaccine supply between endemic and epidemic settings.
    Moore SM; Lessler J
    J R Soc Interface; 2015 Oct; 12(111):20150703. PubMed ID: 26423441
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathways to a policy for cholera control in India.
    Sekhar A; Kang G
    Vaccine; 2020 Feb; 38 Suppl 1():A157-A159. PubMed ID: 31266672
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Live oral vaccines against cholera: an update.
    Levine MM; Kaper JB
    Vaccine; 1993; 11(2):207-12. PubMed ID: 8438619
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccines for cholera control: does herd immunity play a role.
    von Seidlein L
    PLoS Med; 2007 Nov; 4(11):e331. PubMed ID: 18044982
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Statement on oral cholera vaccination.
    Can Commun Dis Rep; 1998 Dec; 24():1-4. PubMed ID: 9868845
    [No Abstract]   [Full Text] [Related]  

  • 39. The history of OCV in India and barriers remaining to programmatic introduction.
    Mogasale V; Kanungo S; Pati S; Lynch J; Dutta S
    Vaccine; 2020 Feb; 38 Suppl 1():A41-A45. PubMed ID: 31982258
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The latest on PaxVax’ and Gotovax AB’s cholera vaccine candidates.
    Riedmann EM
    Hum Vaccin Immunother; 2014; 10(8):2142. PubMed ID: 25580484
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.